LAMELLASOME CF NA
Alternative Names: LAMELLASOME CF-NALatest Information Update: 28 Feb 2023
At a glance
- Originator Lamellar Biomedical
- Class Antifibrotics; Exosome therapies; Gene therapies; Nucleic acids
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cystic fibrosis
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Cystic-fibrosis in United Kingdom (Inhalation)
- 13 Mar 2019 Lamellar Biomedical partners with Edinburgh Complex Fluid Partnership and University of Strathclyde to optimise LAMELLASOME™ technology for Cystic fibrosis
- 04 Jan 2019 LAMELLASOME CF NA is available for licensing as of 11 Jan 2019. https://www.lamellar.com/about/commercialisation/